B. Riley analyst Madison El-Saadi initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $179 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating
- RBC lists biotech winners should RFK depart HHS
- RBC lists biotech winners should RFK departure HHS
- Axsome Therapeutics assumed with an Overweight at Wells Fargo
- Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO’s Market Expansion and Patent Strength